Methods of treating skin disorders with caffeic acid analogs


Ontology type: sgo:Patent     


Patent Info

DATE

2013-05-28T00:00

AUTHORS

PRIEBE WALDEMAR , CONRAD CHARLES , MADDEN TIMOTHY

ABSTRACT

Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%. More... »

Related SciGraph Publications

  • 2010-05-11. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 2000-05-25. Pharmaceutical intervention in the JAK/STAT signaling pathway in ONCOGENE
  • 2005-02-21. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity in ONCOGENE
  • 2003-07-02. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells in ONCOGENE
  • 2002-12-04. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells in ONCOGENE
  • 2007-09-20. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials in LEUKEMIA
  • 2005-06. Validating Stat3 in cancer therapy in NATURE MEDICINE
  • 2004-04-29. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis in ONCOGENE
  • 2000-05-25. STAT signaling in head and neck cancer in ONCOGENE
  • 2004-12-12. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model in NATURE MEDICINE
  • 2004-07. A new modality for immunosuppression: targeting the JAK/STAT pathway in NATURE REVIEWS DRUG DISCOVERY
  • 2006-02-13. Regulation of cytokine signaling pathways by PIAS proteins in CELL RESEARCH
  • 2008-11-11. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2005-04-18. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma in ONCOGENE
  • 2004-10-18. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis in ONCOGENE
  • 2004-08-17. Abrogation of IL-6-mediated JAK signalling by the cyclopentenone prostaglandin 15d-PGJ2 in oral squamous carcinoma cells in BRITISH JOURNAL OF CANCER
  • 2006-10-16. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo in ONCOGENE
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/34", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3404", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "name": "PRIEBE WALDEMAR", 
            "type": "Person"
          }, 
          {
            "name": "CONRAD CHARLES", 
            "type": "Person"
          }, 
          {
            "name": "MADDEN TIMOTHY", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/sj.leu.2404948", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012290605", 
              "https://doi.org/10.1038/sj.leu.2404948"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1207383", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002607732", 
              "https://doi.org/10.1038/sj.onc.1207383"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0605-595", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015381130", 
              "https://doi.org/10.1038/nm0605-595"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206479", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041803871", 
              "https://doi.org/10.1038/sj.onc.1206479"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1203483", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005181530", 
              "https://doi.org/10.1038/sj.onc.1203483"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6602055", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044766274", 
              "https://doi.org/10.1038/sj.bjc.6602055"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd1441", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052520918", 
              "https://doi.org/10.1038/nrd1441"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.cr.7310027", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018273845", 
              "https://doi.org/10.1038/sj.cr.7310027"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1210031", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031711164", 
              "https://doi.org/10.1038/sj.onc.1210031"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6605691", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012090202", 
              "https://doi.org/10.1038/sj.bjc.6605691"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1162", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009892213", 
              "https://doi.org/10.1038/nm1162"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206047", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007790572", 
              "https://doi.org/10.1038/sj.onc.1206047"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1208159", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002882040", 
              "https://doi.org/10.1038/sj.onc.1208159"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-008-0618-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017776294", 
              "https://doi.org/10.1007/s00262-008-0618-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1208635", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040916359", 
              "https://doi.org/10.1038/sj.onc.1208635"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1208470", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049947113", 
              "https://doi.org/10.1038/sj.onc.1208470"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1203550", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021904486", 
              "https://doi.org/10.1038/sj.onc.1203550"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2013-05-28T00:00", 
        "description": "

    Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.

    ", "endDate": "2030-09-06", "id": "sg:patent.US-8450337-B2", "name": "Methods of treating skin disorders with caffeic acid analogs", "sameAs": [ "https://app.dimensions.ai/details/patent/US-8450337-B2" ], "sdDataset": "patents", "sdDatePublished": "2022-11-24T21:22", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/patent/patent_28.jsonl", "type": "Patent" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-8450337-B2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-8450337-B2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-8450337-B2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-8450337-B2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    100 TRIPLES      14 PREDICATES      32 URIs      9 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:patent.US-8450337-B2 schema:about anzsrc-for:34
    2 anzsrc-for:3404
    3 schema:author N08f235c33ddb4f38a623bd3dfd80cc1f
    4 schema:citation sg:pub.10.1007/s00262-008-0618-y
    5 sg:pub.10.1038/nm0605-595
    6 sg:pub.10.1038/nm1162
    7 sg:pub.10.1038/nrd1441
    8 sg:pub.10.1038/sj.bjc.6602055
    9 sg:pub.10.1038/sj.bjc.6605691
    10 sg:pub.10.1038/sj.cr.7310027
    11 sg:pub.10.1038/sj.leu.2404948
    12 sg:pub.10.1038/sj.onc.1203483
    13 sg:pub.10.1038/sj.onc.1203550
    14 sg:pub.10.1038/sj.onc.1206047
    15 sg:pub.10.1038/sj.onc.1206479
    16 sg:pub.10.1038/sj.onc.1207383
    17 sg:pub.10.1038/sj.onc.1208159
    18 sg:pub.10.1038/sj.onc.1208470
    19 sg:pub.10.1038/sj.onc.1208635
    20 sg:pub.10.1038/sj.onc.1210031
    21 schema:datePublished 2013-05-28T00:00
    22 schema:description <p num="p-0001">Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.</p>
    23 schema:endDate 2030-09-06
    24 schema:name Methods of treating skin disorders with caffeic acid analogs
    25 schema:sameAs https://app.dimensions.ai/details/patent/US-8450337-B2
    26 schema:sdDatePublished 2022-11-24T21:22
    27 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    28 schema:sdPublisher Nfe1ec7c1954746baa296ad6578ed0828
    29 sgo:license sg:explorer/license/
    30 sgo:sdDataset patents
    31 rdf:type sgo:Patent
    32 N08f235c33ddb4f38a623bd3dfd80cc1f rdf:first Ncca27eb71e6f4adb83fb5b592b741842
    33 rdf:rest N57fb6131462c4fce82cccca8320d0088
    34 N4234d594a15340c981dcf894241d6a76 rdf:first Nc2048162dca845149c7806c5fad412f1
    35 rdf:rest rdf:nil
    36 N57fb6131462c4fce82cccca8320d0088 rdf:first N6df202731a534cd49073e4faee54a1c9
    37 rdf:rest N4234d594a15340c981dcf894241d6a76
    38 N6df202731a534cd49073e4faee54a1c9 schema:name CONRAD CHARLES
    39 rdf:type schema:Person
    40 Nc2048162dca845149c7806c5fad412f1 schema:name MADDEN TIMOTHY
    41 rdf:type schema:Person
    42 Ncca27eb71e6f4adb83fb5b592b741842 schema:name PRIEBE WALDEMAR
    43 rdf:type schema:Person
    44 Nfe1ec7c1954746baa296ad6578ed0828 schema:name Springer Nature - SN SciGraph project
    45 rdf:type schema:Organization
    46 anzsrc-for:34 schema:inDefinedTermSet anzsrc-for:
    47 rdf:type schema:DefinedTerm
    48 anzsrc-for:3404 schema:inDefinedTermSet anzsrc-for:
    49 rdf:type schema:DefinedTerm
    50 sg:pub.10.1007/s00262-008-0618-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1017776294
    51 https://doi.org/10.1007/s00262-008-0618-y
    52 rdf:type schema:CreativeWork
    53 sg:pub.10.1038/nm0605-595 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015381130
    54 https://doi.org/10.1038/nm0605-595
    55 rdf:type schema:CreativeWork
    56 sg:pub.10.1038/nm1162 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009892213
    57 https://doi.org/10.1038/nm1162
    58 rdf:type schema:CreativeWork
    59 sg:pub.10.1038/nrd1441 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052520918
    60 https://doi.org/10.1038/nrd1441
    61 rdf:type schema:CreativeWork
    62 sg:pub.10.1038/sj.bjc.6602055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044766274
    63 https://doi.org/10.1038/sj.bjc.6602055
    64 rdf:type schema:CreativeWork
    65 sg:pub.10.1038/sj.bjc.6605691 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012090202
    66 https://doi.org/10.1038/sj.bjc.6605691
    67 rdf:type schema:CreativeWork
    68 sg:pub.10.1038/sj.cr.7310027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018273845
    69 https://doi.org/10.1038/sj.cr.7310027
    70 rdf:type schema:CreativeWork
    71 sg:pub.10.1038/sj.leu.2404948 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012290605
    72 https://doi.org/10.1038/sj.leu.2404948
    73 rdf:type schema:CreativeWork
    74 sg:pub.10.1038/sj.onc.1203483 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005181530
    75 https://doi.org/10.1038/sj.onc.1203483
    76 rdf:type schema:CreativeWork
    77 sg:pub.10.1038/sj.onc.1203550 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021904486
    78 https://doi.org/10.1038/sj.onc.1203550
    79 rdf:type schema:CreativeWork
    80 sg:pub.10.1038/sj.onc.1206047 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007790572
    81 https://doi.org/10.1038/sj.onc.1206047
    82 rdf:type schema:CreativeWork
    83 sg:pub.10.1038/sj.onc.1206479 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041803871
    84 https://doi.org/10.1038/sj.onc.1206479
    85 rdf:type schema:CreativeWork
    86 sg:pub.10.1038/sj.onc.1207383 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002607732
    87 https://doi.org/10.1038/sj.onc.1207383
    88 rdf:type schema:CreativeWork
    89 sg:pub.10.1038/sj.onc.1208159 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002882040
    90 https://doi.org/10.1038/sj.onc.1208159
    91 rdf:type schema:CreativeWork
    92 sg:pub.10.1038/sj.onc.1208470 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049947113
    93 https://doi.org/10.1038/sj.onc.1208470
    94 rdf:type schema:CreativeWork
    95 sg:pub.10.1038/sj.onc.1208635 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040916359
    96 https://doi.org/10.1038/sj.onc.1208635
    97 rdf:type schema:CreativeWork
    98 sg:pub.10.1038/sj.onc.1210031 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031711164
    99 https://doi.org/10.1038/sj.onc.1210031
    100 rdf:type schema:CreativeWork
     




    Preview window. Press ESC to close (or click here)


    ...